Key Takeaways

  • The U.S. Food and Drug Administration approved cyclodextrin (brand name Adrabetadex) on November 17, 2026, for infants with Niemann-Pick Type C (NPC) disease.
  • Research supported by the National Institutes of Health (NIH) indicates that the medication extended survival in clinical trial participants affected by this rare genetic disorder.
  • The approval represents twenty years of foundational research and international clinical trial collaborations.

What the Source Says

According to the NIH and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Niemann-Pick Type C is a rare, rapidly fatal neurodegenerative condition affecting children. Research suggests that a mutation in the NPC1 gene prevents regular protein activity, causing cholesterol and lipids to accumulate abnormally within cells. This disruption leads to progressive neurological impairment, developmental delays, and premature death. The source notes that children with NPC may experience cognitive decline similar to dementia seen in older adults.

Scientists first identified the location of the genetic mutation on chromosome 18 in 1997, followed by natural history study monitoring in 2006. Subsequent clinical research, conducted alongside Beren Therapeutics and Rush University Medical Center, evaluated survival outcomes among trial participants. Data analyzed from these efforts demonstrated that cyclodextrin helped lengthen the lifespan of infants diagnosed with the condition, leading to regulatory approval.

Practical Notes

Although NPC primarily affects young children—with half of all cases identified before age 10—understanding cellular transport and genetic mechanisms provides insight into complex health conditions. Specific medication dosages and potential side effects are not specified in the source; please check the official notice.

If you or your family members have questions about rare genetic disorders or developmental health issues, please talk to your doctor.

🩺 Read the Original Source

Source: NIH News Releases · Published November 18, 2026 · Photo by Herlambang Tinasih Gusti on Unsplash

This article is for general information only and is not medical advice. Talk to your doctor before making health decisions.

Related Articles

NIH research team lays groundwork for new treatment of Neimann-Pick Type C in infantsNIH research team lays groundwork for new treatment of Neimann-Pick...Middle-aged and older adults favor TV and YouTube for home exercise, survey findsMiddle-aged and older adults favor TV and YouTube for home exercise...The 5 best breads for blood sugar, according to dietitiansThe 5 best breads for blood sugar, according to dietitiansWhat’s the bare minimum workout for healthy aging?What’s the bare minimum workout for healthy aging?